Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in Sub-Saharan Africa

Andrew N. Phillips, John Stover, Valentina Cambiano, Fumiyo Nakagawa, Michael R. Jordan, Deenan Pillay, Meg Doherty, Paul Revill, Silvia Bertagnolio

Research output: Contribution to journalArticlepeer-review

Abstract

To inform the level of attention to be given by antiretroviral therapy (ART) programs to HIV drug resistance (HIVDR), we used an individual-level model to estimate its impact on future AIDS deaths, HIV incidence, and ART program costs in sub- Saharan Africa (SSA) for a range of program situations. We applied this to SSA through the Spectrum-Goals model. In a situation in which current levels of pretreatment HIVDR are over 10% (mean, 15%), 16% of AIDS deaths (890 000 deaths), 9% of new infections (450 000), and 8% ($6.5 billion) of ART program costs in SSA in 2016-2030 will be attributable to HIVDR.

Original languageEnglish (US)
Pages (from-to)1362-1365
Number of pages4
JournalJournal of Infectious Diseases
Volume215
Issue number9
DOIs
StatePublished - May 1 2017

Keywords

  • HIV
  • cost
  • death
  • drug resistance
  • incidence
  • mathematical model

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in Sub-Saharan Africa'. Together they form a unique fingerprint.

Cite this